Literature DB >> 18320437

Live birth following preimplantation genetic screening for trisomy 21. Should aneuploidy screening be offered to all older patients undergoing IVF?

Stuart Lavery1, Salem A El-Shawarby, Martha Moissidou, Debbie Taylor, Cathy Turner, Ben Lavender, Geoffrey Trew, Raul Margara, Robert Winston.   

Abstract

A 42-year-old female patient with history of secondary infertility was referred to our assisted conception unit for in vitro fertilization (IVF). Before her referral, she had two cycles of IVF at another centre; the first was unsuccessful and, after conceiving at the second attempt, the pregnancy was terminated at 14 weeks' gestation following a positive nuchal translucency scan and a diagnosis of trisomy 21 (Down syndrome) by a chorionic villous biopsy performed in the first trimester. The screening tests for trisomy 21 were offered to the patient in view of her advanced age. Subsequent karyotyping revealed that both partners had a normal chromosomal complement. Following genetic counselling, the couple were offered IVF treatment along with preimplantation genetic screening for trisomy 21. Four of the five embryos were suitable for biopsy, and one blastomere from each embryo was analyzed using fluorescent in situ hybridization for chromosome 21. The analysis revealed that two embryos had trisomy 21, one had monosomy 21, and only one embryo was diploid for chromosome 21. The single diploid embryo was transferred to the uterus on day 3, and resulted in an uneventful pregnancy and delivery of a healthy live-born male.

Entities:  

Mesh:

Year:  2008        PMID: 18320437     DOI: 10.1080/14647270701541087

Source DB:  PubMed          Journal:  Hum Fertil (Camb)        ISSN: 1464-7273            Impact factor:   2.767


  1 in total

1.  Case Report: Twin Pregnancy Gives Birth to a Girl with Partial Trisomy 21 Mosaicism after in vitro Fertilization and Embryo Transfer.

Authors:  Zhenglong Guo; Bing Kang; Dong Wu; Hai Xiao; Leilei Hao; Bingtao Hao; Shixiu Liao
Journal:  Front Genet       Date:  2022-02-03       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.